Skip to content

This site is intended for healthcare professionals in the UK only. Prescribing information and Adverse Event (AE) reporting details can be found in the footer.

  • Why Zegluxen®
    • Therapeutic indications
    • Clinical efficacy
    • Mechanism of action
    • Patient eligibility
  • Cost savings
  • How to Administer
    • Dose Titration
    • Storage and shelf life
    • Method of administration
  • Safety & Tolerability
    • Possible side effects
    • Special warnings and precautions for use
    • Special populations
    • Drug interactions
  • Supporting information
    • FAQs
  • Why Zegluxen®
    • Therapeutic indications
    • Clinical efficacy
    • Mechanism of action
    • Patient eligibility
  • Cost savings
  • How to Administer
    • Dose Titration
    • Storage and shelf life
    • Method of administration
  • Safety & Tolerability
    • Possible side effects
    • Special warnings and precautions for use
    • Special populations
    • Drug interactions
  • Supporting information
    • FAQs

| November 2024

Prescribing information can be found here

  • Navigation
    • Terms of Use
    • HCP Privacy
    • Cookies Policy
    • GDPR

MORE ABOUT US

linkedin

Reporting of side effects

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Zentiva Pharma UK Ltd via our online form (https://www.zentiva.co.uk/contact/mi-form), by email (UKMedInfo@zentiva.com) or by telephone (0800 090 2408).

Copyright Zentiva Group, a.s. © 2026

I confirm I am a UK Healthcare Professional (HCP)

This page is dedicated to UK HCPs only. If you are not a UK HCP, you will be directed to the gateway page after clicking on No.

No, I am not Yes, I am